These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2005-001005-26 A single-arm phase II study of dose-dense gemcitabine and carboplatin as neoadyuvant chemotherapy, with pegfilgrastim support for subjects with operable stage IIIA NSCLC not-yet-due
Listed as ongoing, but also has a completion date 2006-003568-73 Estudio fase III, multicéntrico, abierto, randomizado de tratamiento con erlotinib (Tarceva®) versus quimioterapia en pacientes con carcinoma no microcítico de pulmón avanzado que presentan mutaciones... 2008-10-15 bad-data
Completed, but no date, and reported results 2007-000067-15 Estudio aleatorizado de quimioterapia adyuvante individualizada según los niveles de ARNm de BRCA1 en pacientes con cáncer de pulmón no microcítico (estadios II-IIIA) bad-data
Completed, but no date, and reported results Terminated 2007-004278-20 Estudio aleatorizado fase III multicéntrico para evaluar el tratamiento individualizado valorando BRCA1 en pacientes con cáncer de pulmón no microcítico avanzado. BREC Study (BRCA1 expression customi... bad-data
Completed, but no date, and reported results Terminated 2009-011327-31 Estudio de pemetrexed y cisplatino como tratamiento de primera línea en pacientes con cáncer de pulmón no escamoso, avanzado: estudio farmacogenómico en fase IIA bad-data
Reported results Terminated 2010-022927-31 Ensayo clínico fase II aleatorizado de vinorelbina oral y cisplatino como tratamiento de inducción y después con radioterapia concomitante frente a cisplatino y etopósido con radioterapia concomitante... 2017-04-16 due-trials
Ongoing 2014-004946-83 A phase III prospective double blind placebo controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancer not-yet-due
Completed, report not yet due 2015-003312-21 Phase II clinical trial with tri-weekly metronomic oral vinorelbine and cisplatin as induction treatment for and subsequent concomitant with radiotherapy (RT) in patients with non small cell lung canc... 2019-12-16 not-yet-due
Ongoing 2016-004353-32 Survival, quality of life and self-reported outcomes of elderly patients with advanced non-small cell lung cancer (NSCLC), treated with pembrolizumab (MK-3475) in the first line setting not-yet-due
Ongoing 2016-004524-38 A phase II exploratory study of durvalumab (MEDI4736) in HIV-1 patients with advanced solid tumors not-yet-due
Ongoing 2017-003947-39 A Phase II open-label multicenter exploratory study to assess efficacy of Pembrolizumab re-challange as second or further line in patients with advanced non - small cell lung cancer not-yet-due
Ongoing 2017-004822-13 An Open Label Phase II Study of Tipifarnib in Advanced Squamous Non-small Cell Lung Cancer with HRAS mutations not-yet-due
Ongoing 2017-005154-11 Phase II non-randomized study of Atezolizumab (MPDL3280A) in combination with Carboplatin Plus Pemetrexed in patients who are chemotherapy-naïve and have stage IV non-squamous non-small cell lung canc... not-yet-due
Ongoing 2018-004515-45 A randomized phase II study of neo-adjuvant chemo/immunotherapy versus chemotherapy alone for the treatment of locally advanced and potentially resectable non-small cell lung cancer (NSCLC) patients not-yet-due
Ongoing 2018-004654-17 A phase II open-label study of Atezolizumab in combination with bevacizumab as first line treatment for locally advanced or metastatic high-intermediate tumour mutation burden (TMB) selected non-squam... not-yet-due
Ongoing 2019-002369-36 Clinical Utility of Liquid Biopsy as a tool to assess the evolution of brigatinib treated patients with non-small cell lung cancer with EML4-ALK translocation: an exploratory study not-yet-due